Keyphrases
Afatinib
40%
Anticancer Drugs
40%
Blood Vessels
40%
CD31
20%
Digital Image Analysis
100%
Distribution Studies
100%
Drug Design
20%
Drug Distribution
100%
Drug Efficacy
20%
Drug Imaging
100%
Drug Levels
60%
Drug Substance
20%
Erlotinib
40%
FaDu
20%
Heterogeneous Distribution
20%
Histopathological Features
20%
Immunohistochemistry
20%
Immunohistochemistry Image
100%
Matrix-assisted Laser Desorption Ionization (MALDI)
100%
Microscopic Level
20%
Pharmacokinetic Properties
20%
Sarcoma
40%
Small Vessels
20%
Sorafenib
20%
Sorafenib Treatment
20%
Squamous Cell Carcinoma (SqCC)
20%
Treatment Scheme
20%
Tumor
40%
Tumor Region
60%
Tumor Tissue
20%
Vascularization
40%
Vessel Localization
20%
Vessel Size
20%
Xenograft
40%
Xenograft Model
20%
Medicine and Dentistry
Afatinib
33%
Anticarcinogen
33%
Drug Distribution
100%
Drug Efficacy
16%
Erlotinib
33%
Image Analysis
100%
Immunohistochemistry
100%
Matrix-Assisted Laser Desorption-Ionization
100%
Neoplasm
100%
Pharmacokinetics
16%
Sarcoma
33%
Sorafenib
33%
Squamous Cell Carcinoma
16%
Vascular Bundle
33%
Vascularity
33%
Xenograft
50%
Biochemistry, Genetics and Molecular Biology
Afatinib
40%
Anticancer
40%
CD31
20%
Drug Concentration
60%
Drug Distribution
100%
Drug Efficacy
20%
Erlotinib
40%
Matrix-Assisted Laser Desorption/Ionization
100%
Mouse
40%
Pharmacokinetic Properties
20%
Sorafenib
40%
Vascularization
40%
Pharmacology, Toxicology and Pharmaceutical Science
Afatinib
33%
Anticarcinogen
33%
Drug Distribution
100%
Erlotinib
33%
Matrix-Assisted Laser Desorption/Ionization
100%
Mouse
33%
Neoplasm
100%
Pharmacokinetics
16%
Sarcoma
33%
Sorafenib
33%
Squamous Cell Carcinoma
16%
Immunology and Microbiology
CD31
20%
Drug Concentration
60%
Drug Distribution
100%
Drug Efficacy
20%
Matrix-Assisted Laser Desorption-Ionization
100%
Mouse
40%
Pharmacokinetics
20%
Sorafenib
40%
Squamous Cell
20%
Vascularization
40%
Xenograft
60%